5-ALA under filtered light is limited and cumbersome. The surgical field appears dark, while tumor tissue is stained purple. Coagulation and the dissection of vessels or non-tumorous tissue are either complicated or unfeasible. The interpretation of fluorescence remains largely subjective, particularly at the tumor margins, necessitating permanent switching from bluefiltered to white light. Furthermore, the therapeutic value of 5-ALA has been shown for HGG but not for other malignant cerebral tissue, such as cerebral metastases (30) .
Fluorescein sodium (FL), a fluorophore that has been wellknown in ophthalmic surgery for almost five decades, has been increasingly used and researched in neuro-oncologic surgery since the late 1990s. Based on several publications by the active group of Toshihiko Kuroiwa (23, 24) , the intraoperative use of FL in combination with a dedicated surgical microscope filter has become a matter of great scientific and clinical interest around the world. Today, neurosurgical centers are increasingly equipped with the technical requirements for the intraoperative use of FL. Recently, the First National European Pharmacologic Agency has approved FL for use in neurosurgery (Agenza Italiana del Farmaco'AIFA', determina n.905/2015, 15 luglio 2015).
In this review, we provide the history of FL in neurosurgery and give an overview on current trials and future concepts for using FL for the treatment of malignant brain tumors. The synthetic organic compound FL was discovered by Adolf von Baeyer in 1871. So far, FL has been widely used as a fluorescent tracer in technical chemistry, microscopy, serology, and forensics. Poured into water, the powder colored red or dark orange immediately turns yellow. Exposure to special (yellow-filtered) light with a wavelength of approximately 560 nanometers (nm) significantly increases the color intensity (http://chemfinder.cambridgesoft.com).
Blood-Brain Barrier (BBB) and Cerebral lesions
The blood-brain barrier is characterized by tight interendothelial cell junctions and adjacent astrocyte end feet separated by basal lamina surrounding the endothelium (26) . An intact BBB defends the central nervous system (CNS) from intrusion of foreign substances and maintains CNS homeostasis, including ionic and fluid balances (18) . Abbott et al. could show that the balance of this microenvironment is disrupted by cerebral lesions such as gliomas. The disturbance of the integrity leads to (increased) vascular permeability and 'leakage of fluid into the brain parenchyma which results in high pressure and brain edema (1) . 
months).
No difference in postoperative neurological performance was observed (7).
In 2013, Liu et al. presented the results of a prospective study concerning the combination of MR-diffusion tensor imaging (DTI) and intraoperative tumor-staining with FL (n=83; fixed doses: 10 ml of 10% FL in adults and 0.3 ml/kg bodyweight in children) in patients with glioma in eloquent areas. Both GTR and paralysis rates differed significantly between the 'experimental' FL group and the control group (80.4% versus 40.7%, and 25.0% versus 66.7%, respectively). Consequently, the authors concluded that FL-guided resection increases the rate of GTR and improves quality of life compared to traditional glioma surgery (28) . The summarized characteristics of these studies and the GTR rate are presented in Table IA .
Low-dose FL and dedicated filters:
For neurosurgical purposes, members of the Toshihiko Kuroiwa group from Japan were the pioneers who revitalized the investigation into FL to improve the quality of resection of malignant brain tumors. In a report on 10 patients with HGG, the authors described the modification of a conventional surgical microscope that had been equipped with a xenon lamp 'Superlux'300, a BP 450-490 nm excitation filter (Zeiss, Germany), and a KODAK Wratten No.12 barrier filter (500-530 nm). 8 mg of FL per kg of bodyweight were injected after durotomy, and tumor dissection started about 20 minutes afterwards. In all patients, intraoperative fluorescence seemed to correspond well with the areas of gadolinium-enhancement in the preoperative MRI. An 80% rate of complete resection was confirmed by postoperative computed tomography (CT) or MRI. The authors concluded that fluorescent staining was due to the lack of normal blood-brain barrier function and that the combination of i.v. FL-injection and microscope filter maybe useful in glioma surgery (23) .
Based on these encouraging findings, the same group published their personal experiences with FL in 1999, concluding that 'this method is very useful for exhibiting regions that lack the blood-brain barrier, where images are enhanced on CT scans and MR images' (24). was 80%, and, in the remaining patients, the mean EOR was 92.6% (3). Mitchel Berger commented on this paper outlining the great potential of FL-guided resection of HGG in an editorial and emphasized the necessity of further large prospective series (5).
In 2015, the Indianapolis group reported on 12 prospectively enrolled patients with HGG. All patients were operated on by means of the FL-guided technique under the Y560 filter. The rate of complete resection was 100% −as proven by early postoperative contrast-enhanced MRI− and intraoperative neuro-navigation (contrast-enhanced T1 weighted sequences) corresponded well to the fluorescing areas. According to the authors, this finding strongly supports the impression that Gd-enhanced MRI is equivalent to FL fluorescence in HGG. Furthermore, the authors provided an analysis of FL accuracy and reported sensitivity and specificity rates of 82.2% and 90.9% (11) .
The summarized characteristics of these studies and the GTR rate are presented in Table IB . The calculated sensitivity and specificity rates of FL in combination with the Y560 nm filter are presented in Table II . In contrast to conventional FL, albumin-conjugated fluorescein was significantly brighter under the microscope, and fluorescence lasted significantly longer. Furthermore, albumin-conjugated fluorescein was entrapped in the tumor, whereas FL was also found in damaged BBB in other tissue (19) .
In 2014, Martirosyan et al. provided experimental data on the useof a confocal endomicroscope in combination with various fluorophores in a rodent-glioma model (n=25). Among the evaluated dyes were FL, 5-ALA, acridine orange, acriflavine, and cresyl violet. Within 5 minutes after the injection, tumor areas with disrupted BBB were characterized by extravasation of FL. Additionally, cytoarchitectural characteristics could be exactly determined, and qualitative fluorescence intensity was in the highest range. Thus, the authors concluded that handheld confocal microscopy with FL represents a useful tool for real-time in vivo histopathological assessment and visualization of malignant cerebral lesions (32) . In the same issue of Acta Neurochirurgica, the Italian group of Francesco Acerbi published the preliminary results of the FLUOGLIO study. 12 patients with HGG had been enrolled and analyzed: the rate of complete resection was 75%, and histological analysis confirmed a high accuracy of using fluorescein for tumor identification. The calculated rates for sensitivity and specificity were 91% and 100% (2).
In 2014, the Indianapolis group of Aaron Cohen-Gadol focused on the accuracy of tissue diagnosis during stereotactic needle biopsy after administration of 3 mg of FL per kg of bodyweight. 26 specimens from 6 patients with suspected HGG were obtained. The calculated rates for sensitivity and specificity were 79% and 100% (42) .
Additional data on the quality of fluorescence staining in HGG were provided by Acerbi et al. in 2014. Again, preliminary data from the FLUOGLIO trial (n=29) showed sensitivity and specificity rates for FL of 94.0% and 89.5%. The GTR rate only 4 patients developed local recurrence during the followup (median 8 months). The authors concluded that −compared to conventional surgery− use of FL may decrease recurrence rates (38) .
In 2015, the authors of this review published the first report on the use of FL under the Y560 filter in 30 patients with CM. Bright fluorescent staining was found in 90% of the patients, and the GTR rate was 83.3% (45) . In an editorial to this report, Gempt and Meyer supported our impression that FL may be beneficial in CM surgery. However, large prospective studies are mandatory to confirm the efficacy of FL (16).
The different microscopic views are shown in Figures 4A , B. Figure 4A shows white light and Figure 4B fluorescent staining that exactly demarcates the localization of subcortical metastasis.
Meningiomas and Skull Base Tumors
Da Silva et al. reported on a prospective mini-series of 6 patients with skull base tumors (1 acoustic neuroma, 3 meningiomas, 1 craniopharyngioma, 1 pituitary adenoma), who were operated on after an injection of 1000 mg of 20% FL under white light illumination. Particularly in meningiomas, dural enhancement was clearly visible that may have been due to dural infiltration of the tumors. However, this issue was not investigated further (8, 9 In Figures 3A-C, the same specimen is shown under different visualization modes. In Figure 3A , white light is applied to a specimen without any visible tumor tissue. In Figure 3B , the Y560 nm filter is activated, and the yellow fluorescing spot demarcates the suspicious area. HE staining is shown in Figure 3C , clearly depicting the tumorous area similar to the fluorescing spot.
█ USE of Fl in NON-glIOMA lESIONS
In 2010, the indication for fluorescence-guided surgery with FL for brain tumors was extended to cerebral metastases and skull base tumors.
Cerebral Metastases (CM)
Okuda et al. presented a retrospective analysis of 36 patients with CM from various primary cancers, who underwent microsurgery under white light after the injection of high-dose FL (20 mg/kg bodyweight). Complete resection was achieved in 31 of 36 patients, and 20 patients were not assigned to adjuvant whole brain radiotherapy (WBRT). Out of this group, 
█ OFF-lABEl USE and REpORTINg on ADvERSE EvENTS
The Italian Agency of Pharmacology (AIFA) was the first European authority that approved FL for use in neurosurgery in July 2015 (Agenza Italiana del Farmaco 'AIFA', determina n.905/2015, 15 luglio 2015). In all other countries, FL must be used off-label, and patients must preoperatively provide written informed consent.
The same group provided a report on 5 frontal convexity meningiomas that had been resected after the injection of 1000 mg of 20% FL. The 'dural tail', as indicated by MRI, corresponded well with the intraoperative findings, and histopathological analysis confirmed the correlation between fluorescence and tumor infiltration (10) .
Although the reports about the use of FL in meningiomas and other (benign) skull base tumors were promising, prospective studies with larger cohorts are necessary to confirm the efficacy and benefit of FL-guided surgery in these entities.
primary Central Nervous System lymphoma (pCNSl)
The first description of the use of FL in PCNSL surgery was provided by Okuda et al. High-dose FL was injected after the opening of the dura. Fluorescent staining was observed in stereotactic needle biopsies as well as endoscopically. The authors concluded that FL was effective in the diagnosis and surgery of PCNSL (37) .
In cooperation with the Italian group of Francesco Acerbi, the authors of this review retrospectively analyzed the data of 7 patients who had the diagnosis of PCNSL confirmed by the final histological examination. The preoperative contrastenhanced MRI of these patients showed distinct contrastenhanced lesions strongly suspicious of CM or HGG. Because 
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The FLUOGLIO trial (Eudra CT no. 2011-002527-18) is a multicenter phase-II trial that has been designed according to the 5-ALA trial (49) with similar primary and secondary endpoints. The primary endpoint is the rate of complete resection in the early postoperative volumetric contrastenhanced T1-weighted MR-sequence. Secondary endpoints are PFS, OS, neurological outcome, and the toxicity of FL. To date, Acerbi et al. have provided two publications with preliminary data (2,3) , showing a rate of complete resection in 80% of the patients with HGG.
The final evaluation and publication of the FLUOGLIO trial data are scheduled for 2016. Presumably, the results will confirm the excellent GTR rates of the retrospective series presented in this review.
A very important and promising ongoing study on the accuracy and benefit of FL-guided surgery has been outlined during To further evaluate the effect of FL under the Y560 filter, a phase trial III has been designed in which a large cohort of patients will be included. This study under Italian leadership has been planned as a multicenter, prospectively randomized, and controlled trial. Two case reports have described severe adverse events after the injection of FL for neurosurgical purposes (13, 52) . Both patients underwent resection of HGG after the injection of high-dose FL, but only for 1 patient was the dose specified with 20 mg/kg bodyweight. Both patients suffered severe hypotension during general anesthesia, and, in one patient, surgery had to be discontinued. Both patients had to be admitted to the intensive care unit and fully recovered after the administration of adrenalin, prednisolone, and atropine.
We could not find any further reports on anaphylactic or severe allergic reactions in the current literature. However, all authors have described the immediate but transient yellow discoloration of the skin and the urine −due to quick renal excretion of FL-for a maximum of 24 hours.
Despite the very low risk of any severe adverse reactions due to low-dose i.v. injection of FL, neurosurgeons should be aware of any liver and kidney dysfunction, pulmonary spasm, and history of allergic reactions to contrast dye. In such cases, use of FL should be reconsidered.
█ CURRENT CONCEpTS (pRElIMINARy DATA and ONgOINg TRIAlS)
FL can be used under white light or under a dedicated surgical microscope filter. The use with white light requires doses up to 20 mg/kg bodyweight, whereas the dose can be reduced to 2 -4 mg/kg under a light filter (e.g. Y560). Because we are highly experienced in using low-dose FL under filtered light, we thoroughly recommend this combination.
Fluorescence-guided surgery with FL under a dedicated surgical microscope filter is becoming increasingly established worldwide. Many neurosurgeons are deeply impressed by the possibilities and advantages of FL. First of all, the quality of the visualization of the surgical field is excellent. After a few operations, surgeons will increasingly use the filter mode because dissection and coagulation can be easily conducted without affecting the operative work flow by having to switch to the white light mode.
Another important issue is the ready availability and accessibility of FL, its very low purchase cost, and its very few adverse effects. In contrast to 5-ALA, FL does not require prevention from light, and no severe skin reactions have been described to the best of our knowledge. Furthermore, FL is completely excreted within 24 hours.
However, the efficacy of FL-guided surgery in malignant brain tumors is still discussed controversially. Since FL is a marker for BBB disruption, some authors have speculated that only unspecific changes in the tumor environment are depicted and that the lesion would not be visualized specifically enough (14) . From our point of view, such concern is inappropriate because the FL-guided technique has repeatedly resulted in high rates of complete resections, particularly in HGG (as mentioned above). Notwithstanding, it is mandatory to present prospective data that prove the efficacy of the FLguided technique surgery beyond question. Such data are presently generated in the FLUOGLIO trial.
As outlined in Tables IA and IB , no retrospective analysis yielded a rate of complete resection or GTR below 80%, irrespective of the mode of illumination. Thus, even FL-guided surgery under white light may be assumed to significantly improve the quality of resection, not only in malignant gliomas, but also in CM, PCNSL, and skull base tumors. Similarly, however, prospective analysis is mandatory to prove the usefulness of FL in non-glioma lesions.
Presently, the literature provides much more scientific data on 5-ALA than on FL. Fluorescence-guided surgery with 5-ALA is certainly efficient and does have its place in neuro-oncologic surgery. Nevertheless, the investigation of innovative technical tools or alternative dyes is important and justified. Therefore, the continuous criticism of some 5-ALA supporters who question the rationale behind the FL-guided technique is difficult to understand (12, 48, 50) . On the other hand, many accredited neurosurgeons such as Mitchell Berger or John Sampson accompany the discussion with thoughtful editorials and recommendations (5, 15) . In the light of the current debate, scientific process may be enhanced by including all experts in the field of modern FL-guided surgery, such as Francesco Acerbi, Peter Nakaji, and Aaron Cohen-Gadol (6).
In short, FL yields the same results as 5-ALA but in a much easier manner. FL is a readily available method for fluorescence-guided tumor resection but is a marker of contrast enhancement rather than a marker of tumors. FL may improve resection with minimal risk, and tumor margins are clearly visualized (Figure 2 ).
The surrogate for complete resection is the contrast-enhanced tumor in the T1-weighted MR-sequence, as recently outlined again by Hadjipanayis et al. In a review on the use of 5-ALA in HGG (17) , the rates of complete resection by means of 5-ALA ranged from 63% to 89%. However, due to its high purchase costs and its limited availability, the use of 5-ALA is restricted to a few countries only. Furthermore, special equipment (surgical microscope filter) and experience is needed to conduct fluorescence-guided surgery with 5-ALA. As one of the few neurosurgical centers in the world, we justifiably claim to have sufficient experience in the use of both fluorescence techniques to assess their usefulness and practicability. We think it more practical to apply the FL-guided technique in almost all types of contrast-enhanced tumors of the brain, in which GTR should be achieved. The illumination of the Y560 filter allows continuous dissection, resection, and coagulation without switching from one light source to the other, as necessary when using the 5-ALA technique. The borders are sharply demarcated and represent the areas of MR-contrast enhancement. FL can be injected during the induction of anesthesia, does not cause any severe adverse effects, and is excreted rapidly. Furthermore, the availability of FL is warranted all over the world, and the costs are almost negligible.
In our opinion, FL-guided surgery provides all scientific preconditions that justify its clinical use and further evaluation in the field of neuro-oncologic surgery.
